We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Arrayjet Secures Protein Microarray Bioprinter Contract with CDI Laboratories

Arrayjet Secures Protein Microarray Bioprinter Contract with CDI Laboratories content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Arrayjet, a Scottish-based microarray instrumentation company, has secured a further contract with US-based Proteomics company, CDI Laboratories, which will further enhance CDI’s work in advancing proteomic research and development.

The contract value is circa $1 million and is the second Arrayjet install at CDI. This new instrument features the IRIS Optical QC system which has a dual camera mounted on either side of the printhead for enhanced QC capabilities.

This follows on from the deployment of Arrayjet’s Ultra Marathon II high throughput microarray printer back in 2015. This has enabled CDI Laboratories to perform efficient analyses of thousands of protein interactions using minimal amounts of valuable research or clinical samples.

CDI Laboratories produces the largest protein microarray in the world.  Printing close to 22,000 proteins on one chip requires the utmost precision and quality regarding spot morphology. Additionally, since the proteins are purified and printed to retain the proteins native conformation, the ability of the printer to maintain consistency in this rigorous environment is vital.

Therefore, CDI will use its new Arrayjet Ultra Marathon II to print its HuProt™ protein microarrays that contain 81% of the human proteome.  In addition, the Ultra Marathon II will be used to print customized protein microarrays and, eventually, antibody microarrays.

CDI expects that the purchase of Arrayjet’s Ultra Marathon II will improve CDI’s ability to print large quantities of protein and antibody microarrays whilst significantly optimizing quality. The laboratory currently has patents in process for a number of related technologies to increase high throughput analysis of protein-to-protein interactions, antibodies and biomarker identification processes.